# SPI-1005 Treatment in Moderate COVID-19 Patients

> **NCT04484025** · PHASE2 · UNKNOWN · sponsor: **Sound Pharmaceuticals, Incorporated** · enrollment: 60 (estimated)

## Conditions studied

- Covid19
- Corona Virus Infection
- Coronavirus
- Coronavirus Infection

## Interventions

- **DRUG:** Ebselen
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04484025
- **Lead sponsor:** Sound Pharmaceuticals, Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-12
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04484025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04484025, "SPI-1005 Treatment in Moderate COVID-19 Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04484025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*